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and interest in undergoing testing. Male respondents were 
more interested in testing compared to females. There was 
a strong interest in genetic research participation and nota-
bly limited privacy concerns.  Conclusion: Although 59% of 
the respondents were interested in DTC genomic testing, 
they were not likely to be affected by them or act upon them. 
This raises questions about concerns relating to potential 
risks of DTC genomics users and users’ understanding of ge-
netic information including their awareness of privacy risks. 
Furthermore, the strong interest in genetic research partici-
pation signals an underexplored personal utility of genomic 
testing which needs to be both better understood and bet-
ter harnessed.  © 2014 S. Karger AG, Basel 
Introduction
 Genetic testing outside the standard clinical setting 
has been available to consumers for over a decade. Sev-
eral companies operating in many countries began by of-
fering mostly single nucleotide polymorphism (SNP) 
analysis from which various kinds of personal genomic 
information is generated. Such companies usually offer a 
combination of the following services to their customers: 
information about the presence/absence of certain genet-
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 Abstract 
 Aims: This study examined the attitudes of 1,146 Swiss Uni-
versity students to direct-to-consumer (DTC) genomic test-
ing and to genomic research participation.  Methods: Data 
were collected through a self-completion online question-
naire by students from 2 higher education institutions in Zu-
rich, Switzerland. The survey aimed to capture motivation 
for undergoing or refraining from genomic testing, reactions 
to mock genetic risk results, and views about contributing 
data to scientific research. Descriptive and inferential statis-
tics were used for the analysis.  Results: A total of 1.5% of the 
students had undergone testing. Most respondents were 
studying natural sciences and were interested in undergo-
ing DTC genomic testing. The main motive was to contribute 
their data to scientific research, followed closely by their in-
terest to find out disease risks and personal traits. Overall, 
41% of the respondents were not interested in DTC tests. The 
primary reasons were concerns about receiving potentially 
worrying results. There was a significant correlation between 
studying natural sciences, as opposed to the humanities, 
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ic traits, disease risk probability, ancestry, and some phar-
macogenomic information. Most companies operate on 
online interfaces, and initially they employed the so-
called direct-to-consumer (DTC) approach whereby us-
ers can order the test online and receive their results di-
rectly without the mediation of health professionals. We 
can refer to this as the pure DTC genomics model. This 
approach hardly comprises the representative model in 
the current phase of commercial personal genomics, yet 
it is the one that has sparked the most excitement and de-
bate. Currently, a number of different models are in op-
eration, whereby health professionals are involved to var-
ious degrees. Commercial personal genomics has ‘rein-
vented’ itself in a number of ways  [1] , probably partly in 
response to the controversy that the pure DTC model 
generated amongst regulators, scientists, bioethicists, and 
the lay press, but also because the uptake of such services 
has to date been limited  [2] . ‘Beyond-the-clinic’ genomics 
is a more accurate term, capturing the variety of practices 
currently available while focusing on their key shared fea-
ture, namely, that they take place beyond the standard 
clinical setting  [3] .
 The debate about the risks and benefits of DTC ge-
nomics focused heavily on arguments about the scientific 
validity and clinical utility of the results, the burden of 
genetic information to those faced with probabilistic data 
as well as concerns about genetic privacy. Proponents of 
DTC genomics services argued about the rights of indi-
viduals to freely access their genetic information, the em-
powering potential of taking action in relation to one’s 
own health, other personal utilities such as increasing ge-
netic literacy, participating in research, and contributing 
to the advancement of scientific knowledge  [4] . However, 
the predominant argument made by those opposing DTC 
genomics services, which was also pre-eminent in the reg-
ulatory debates, concerned the risk of harm to the con-
sumers. In the course of the debates that unfolded in the 
USA  [5] and Europe  [6] , a number of assumptions were 
made about the prospective users, especially in regard to 
their attitudes about, and expectations of, such services as 
well as their overall willingness to use them. Recently, the 
US Food and Drug Administration issued a cease and
desist letter to the leading DTC genomics company
23andMe. While it cited the company’s failure to comply 
with FDA requirements, it also referenced the risks posed 
to consumers by the use of genomic information that they 
received from the company  [7] . It is not uncommon to 
hypothesize about potential risks of emerging technolo-
gies  [8] . Yet, if we are to understand and adequately re-
spond to this ‘disruptive innovation’ in genetic testing, we 
need a more systematic assessment of how individuals 
actually view such options and what is the nature of their 
expectations and experiences with such testing. Such an 
assessment will be valuable for the discourse about pro-
viding appropriate policy frameworks for such services.
 A number of studies have sought to better understand 
actual and prospective DTC genomics users  [9, 10] . While 
some patterns eventually begin to emerge, i.e. in terms of 
users’ motivation, experience with test results, action tak-
en on the basis of such results, and attitudes about test-
taking, empirical data have remained limited. Further-
more, only a few empirical studies have been conducted 
outside North America. DTC genomics services are pri-
marily offered online, easily crossing national borders 
and being available within a global market. It is, therefore, 
important to explore users’ attitudes and experiences be-
yond the Anglo-American context as the different cul-
tural responses to genetics, privacy protections, and 
health care access are likely to produce diverse user pro-
files and will likely affect the risk-benefit ratios associated 
with DTC genomics. We have previously reported on an 
exploratory study of attitudes, motivation, and experi-
ences of Swiss users, specifically users of the commercial 
genetic testing provider 23andMe  [11] . Our findings sug-
gested that the users in the study, mostly life scientists, 
were primarily driven by curiosity and had an overall pos-
itive testing experience. The qualitative analysis revealed 
a strong interest in undergoing DTC genomic testing also 
as a means of participating in scientific research. We at-
tributed this interest to the educational background of the 
study population which included a significant number of 
researchers. Based on these finding, we set out to conduct 
a more comprehensive study with a much larger sample 
that targeted not only users but also those with demo-
graphic characteristics likely to be shared by prospective 
users (higher educational level, internet users, young). 
Our aim was to further explore motivation in relation to 
such testing, including reasons for refraining from testing 
and possible reactions to disease risk probabilities. More-
over, given that our previous study as well as other studies 
has identified research participation as a significant per-
sonal utility of personal genomic testing, we wanted to 
further test the validity of this finding.
 The Swiss Context 
 The legal environment for DTC genomics in Switzer-
land is strictly regulated: Swiss law prohibits genetic and 
genomic testing that is not prescribed by a physician for 
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a medical indication  [12] . Therefore, companies are not 
allowed to offer such services from Swiss territory. This 
law, does not prohibit residents from purchasing such 
services abroad, i.e. online. The Swiss Ministry of Health, 
however, has produced a public information leaflet rec-
ommending Swiss residents to refrain from online genet-
ic tests due to concerns about their quality and concerns 
about data privacy. An independent expert advisory 
body, the Expert Commission on Human Genetic Test-
ing (Expertenkommission für Genetische Untersuchun-
gen beim Menschen (GUMEK)), is appointed by the 
Ministry to provide expert opinion on issues related to 
human ge netics.
 Over the last 2 years, there has been considerable de-
bate about the issue of personal genomics in Switzerland, 
particularly in the German-speaking part of the country. 
Several national organizations and academic institutions 
have developed a strong interest in personalized medi-
cine, nominating it as a research priority area. Against 
this background, the Swiss Academy of Medical Sciences 
has issued an opinion paper on the potential and chal-
lenges of personalized medicine dedicating a significant 
section of it on the problems presented by DTC genomics 
services  [13] . The Swiss Technology Assessment Agency 
has recently completed a study on personalized medicine, 
including substantial reference to DTC genomics  [14] . Fi-
nally, at the request of the Ministry of Health, GUMEK 
has prepared a series of recommendations for the reform 
of the existing genetic testing law. The suggested reforms 
aim to update the law in light of developments such as 
next-generation sequencing, the new challenges of in-
formed consent and counseling in the context of the an-
ticipated data influx, quality control issues, laboratory 
certification, and genetic data protection.
 The proposed reform specifically addresses the issue of 
DTC genomic testing  [15] . GUMEK argues that a prag-
matic approach is needed in dealing with commercial en-
tities providing personal genomics services outside the 
clinical setting. Although it raises serious concerns about 
DTC genomics and highlights the risks posed to consum-
ers, it admits that maintaining the prohibition of such 
services does not advance the protection of citizens, since 
such products are easily accessible on the global market. 
The alternative approach they suggest is to allow the pro-
vision of DTC genomics services in Switzerland under a 
number of well-controlled conditions. These include a 
specific list (negative list) of which types of tests cannot 
be offered, i.e. tests for carrier status of recessive diseases, 
for monogenic diseases, for disease predisposition of rel-
evant penetrance, and for structural chromosomal aber-
rations [ 15 , pp. 32–33]. Other conditions include labora-
tory certification, prohibition of testing of third parties 
and minors including punitive measures extending in 
such cases to consumers, not only to service providers 
(for example in the testing of minors, the adults who sub-
mitted the sample would also face charges). Although it 
is yet to be given legal force, this in an important develop-
ment, signaling a departure from a regime of strict prohi-
bition and so making it possible for DTC genomics com-
panies to emerge in Switzerland. It is therefore of particu-
lar importance to understand potential users’ attitudes 
towards such testing.
 Methodology 
 This study is a survey of attitudes to DTC genomics amongst a 
large sample of students in the Swiss Federal Institute of Technol-
ogy (ETH) and the University of Zurich in Switzerland. All par-
ticipants in this study resided in Switzerland where both public and 
private health expenditure are comparatively high and health in-
surance coverage is universal. We conducted an online anony-
mous survey in 2 sessions between May and June 2013. Upon reg-
istration in the above institutions, students can indicate whether 
they are interested in receiving invitations for online surveys via 
e-mail. The list of e-mails is maintained by the University admin-
istration which distributes survey invitations. An e-mail invitation 
was sent via this office to undergraduate, bachelor, master as well 
as PhD students explaining the goal of the study and including the 
link to a multimedia presentation of internet-based genomic test-
ing and a self-completion questionnaire in German. Permission 
from the research ethics review committee of the canton of Zurich 
was requested and received.
 The multimedia file included a black-and-white animation and 
text describing internet-based genomic testing without an audio 
element. It was developed in collaboration with the Information 
Technology group of the University of Zurich and was reviewed 
for content, design, and presentation by experts in genetics, psy-
chology, social science, medicine, law, ethics, and information 
technology. The survey was developed on the surveymonkey.com 
platform. We designed the questionnaire on the basis of our previ-
ous study and after reviewing similar questionnaires of other pub-
lished studies  [16–18] . Our survey instruments were also reviewed 
by an internal group and were pre-tested. Adjustments were made, 
and the final questionnaire included 31 multiple-choice and 
7-point Likert scale questions. Questions were intended to capture 
motivation for testing and reactions to test results. Furthermore, 
we included a set of questions aimed at exploring the relationship 
between genetic testing and research participation. We hypothe-
sized that the majority of our respondents are unlikely to have had 
real experience, and thus we asked participants to imagine the pos-
sibility of a DTC genomic test and what would be their likely mo-
tives for either undergoing testing or refraining from it. Demo-
graphic data including gender, year of birth, and study subject 
were also collected ( table 1 ).
 We conducted descriptive statistical analysis using SPSS Statis-
tics 20.0. complemented by inferential statistics. More specifically, 
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we conducted Pearson’s χ2 tests to establish associations between 
attitudes to DTC genomics and religiosity, academic background, 
gender, degree of concern over personal health, and views on gene 
versus environment effects on health. Cramer’s V was performed 
to test the strength of association between those categorical vari-
ables. The 7-point-Likert scale scores were split into groups which 
were then compared on different measures with a Pearson’s χ2 test. 
Significance was accepted at a p < 0.05 level. We conducted quali-
tative analysis of the open-ended questions. Answers were post-
coded, but findings are limited as only a small number of respons-
es was available.
 Results 
 A total of 1,146 respondents filled out the survey, rep-
resenting a response rate of 5.6%. This is within the typi-
cal response rate for online surveys administered through 
the University mailing system. Gender was equally repre-
sented in the respondents (50.5% male and 49.5% female 
students). Our cohort was young, with 75% of all partici-
pants between 19–26 years of age. Most students who re-
sponded to the survey studied natural sciences ( table 1 ). 
The heavier representation of natural sciences can be 
partly explained by the fact that the larger number of re-
spondents came from the ETH which offers natural sci-
ence and engineering degrees only. Although we did not 
collect data on nationality, we know that all respondents 
are residents in Switzerland. In terms of non-Swiss stu-
dents, the University of Zurich comprises 12% at the 
bachelor level, 18% at the masters level, and 38% at the 
doctoral level (numbers of 2012)  [19] . In the case of the 
ETH Zurich, 19.6% of all students at the bachelor level are 
non-Swiss as well as 37.9% at the masters level and 66.7% 
at the doctoral level (numbers from 2012)  [20] .
 Approximately two-thirds of the respondents (65.7%) 
were already aware of internet-based DTC genomics. Hu-
manities students were less likely to have heard of DTC 
genomics before the survey compared to natural sci - 
ence/engineering students (χ2 (2, n = 1,107) = 22.782,
p = 0.000). The majority ranked their concern about their 
own health in the middle (mean = 4.3) of a 7-point Likert 
scale ranging from 1 (not at all) to 7 (very much). Only a 
small percentage (10.95%, mean = 2) agreed that religion 
plays a substantial role in their life, and when considering 
to what extent genes or environment affect health, the ma-
jority of the respondents placed it in the middle of 7-point 
Likert scale (mean = 4.3), representing a mix of both.
 Only a very small number of respondents (1.5%, n = 
17) had personal experience with DTC genomics. The 
majority of them studied natural science/engineering and 
medicine. The primary reasons for having had a test were 
an interest in personal traits, ancestry, and a general inter-
est in genetics. The majority of these test takers (86.7%) 
contributed their data to scientific research, and none re-
gretted having undergone testing. Answers to the open 
question about why they did not regret testing included: 
usefulness of information about drug sensitivity and 
health risk information.
 From the remaining respondents who did not have ac-
tual experience with DTC genomics, about 59% were in-
terested in undergoing such a test.  Table 2 shows the re-
spondents’ motives ranked by the number of times each 
reason was chosen. The main motive for undergoing test-
ing was willingness to share the data with the scientific 
community, followed by an interest in finding out about 
disease risk and personal traits. About 41% of the respon-
dents were not interested in undergoing DTC genomic 
testing. The most selected reasons for this were concerns 
about dealing with the results and concerns about the low 
validity and utility of such tests ( table 2 ). 
 We explored the relationship between interest in test-
ing and study subject, gender, religiosity, concerns about 
own health, views about the environment/genes health 
effects. We identified a significant correlation between 
studying natural sciences/engineering and interest in un-
dergoing DTC genomic testing as compared with study-
ing humanities (χ2 (2, n = 1,092) = 7.140, p = 0.028). High 
religiosity was negatively associated with willingness to 
undergo testing (χ2 (1, n = 1,057) = 35.061, p = 0.000). 
Similar to other reports, in our sample male respondents 
were more interested in being tested compared to female 
respondents (χ2 (1, n = 1,123) = 16.857, p = 0.000) ( ta-
ble 3 )  [18, 21, 22] . Furthermore, we found a significant 
relationship between willingness to contribute genetic 
data to scientific research and study subject: those study-
ing science/engineering and medicine were more likely to 
have answered that they would contribute their data com-
pared to those studying humanities (χ2 (2, n = 906) = 
8.890, p = 0.012). While for the former the primary reason 
Table 1.  Demographics of the respondents (n = 1,146)
Mean age, years 25
Gender, n
Females 564
Males 576
Study subject, n
Natural sciences/engineering 881
Humanities 182
Medicine 45
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for testing was contribution to research, for the latter the 
primary reason was receiving the genetic information 
about their personal health risks. We did not observe any 
significant effects when conducting frequency analysis 
amongst all categorical variables (gender, background, 
etc).
 Responses to Hypothetical High/Low Genetic Risk of 
Two Conditions 
 Participants were asked to react to 2 hypothetical re-
sults indicating elevated and decreased risk of colon can-
cer and obesity ( table 4 ). Respondents could choose mul-
tiple reactions from a list of options. We ranked the reac-
tions according to the total number of times they were 
selected. In the scenario of increased colon cancer risk, 
the most likely reaction chosen was to take measures to 
reduce the risk (through screening and lifestyle changes) 
(n = 605) followed by the option of consulting a medical 
doctor (n = 577). The third most chosen option was the 
one suggesting that the results would not have an effect 
on the recipient due to their highly probabilistic nature
(n = 444). The option that results would be alarming was 
ranked lower (n = 406), and very few indicated that these 
results are meaningless and would be completely ignored 
(n = 18). In the case of a decreased colon cancer risk, the 
option chosen most often was the one suggesting that the 
results would not have an effect on the recipient due to 
their highly probabilistic nature (n = 749), followed by the 
option that the results are reassuring (n = 339).
 In the case of an increased risk of obesity ( table 4 ), the 
most commonly chosen reaction was that of taking mea-
sures to decrease risk (through sports, nutrition) (n = 
Table 2.  Respondents’ answers
Response n %
Ranked reasons for undergoing DTC genomic testing a
I would like to contribute my genetic data to scientific research 477 72
I would like to know if I am at risk of certain diseases 440 66
I would like to find out about my genetic traits 436 66
I would like to know the risk of my passing on to my children a predisposition to disease 368 56
I would like to know my sensitivity to certain medication 348 52
I would like to find out about my genetic ancestry 332 50
I am interested in genetics in general 315 48
Just for fun 252 38
If I were able to buy the test at low cost 251 38
I was curious about how such a test works 218 33
Ranked reasons for refraining from DTC genomic testing b
I am concerned that the results will worry me 278 60
I do no think the test results are valid 257 56
I do not see any utility in such tests/I am not interested in my genetic profile 209 45
I am concerned about the privacy of my data 202 44
Cost is an obstacle to undergo testing 111 24
I am skeptical about genetic testing in general 67 17
Ranked reasons for not participating in a genetic study in the clinic
I am concerned that the results will worry me 150 54
Time would be an obstacle to participating 124 45
I am concerned about the privacy of my data 89 32
I am skeptical about genetic testing 56 20
I question the validity of the test 39 14
I am not interested in genetics at all 12 4
 a Furthermore, a χ2 test including the categorical variables gender and background was conducted and revealed 
the following results: females were more likely to be interested in genetics (χ2 (1, n = 661) = 5.371, p = 0.020), and 
students from humanities were less likely to be interested in genetics (χ2 (2, n = 651) = 11.139, p = 0.004) as well 
as in personal traits (χ2 (2, n = 651) = 9.006, p = 0.011).
b Furthermore, a χ2 test including the categorical variable gender was conducted and revealed the following 
result: males were less likely to be concerned about results (χ2 (1, n = 462) = 13.864, p = 0.000).
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553), followed closely by the option of feeling unaffected 
due to the highly probabilistic nature of results (n = 505). 
In the case of a decreased obesity risk scenario ( table 4 ), 
responses were similar to the decreased colon cancer 
risk: the option chosen most often was the one suggesting 
that the results would not have an effect on the recipient 
due to their highly probabilistic nature (n = 705). The 
second most chosen option was the one indicating a 
sense of reassurance about good health (n = 252). In gen-
eral, when we compared good and bad results (low- and 
high-risk probability of developing either disease) to pri-
mary reactions, we found that good results led to more 
doubts about the utility of the tests compared to bad ones 
(χ2 (1, n = 1,146) = 90.044, p = 0.000). When we com-
pared specific reactions with interest or not in undergo-
ing testing, we found that students who were not inter-
ested in DTC genomic testing were more likely to think 
that results (good or bad) were not valid (for increased 
colon cancer risk: χ2 (1, n = 1,128) = 7.301, p = 0.007; for 
increased obesity risk: χ2 (1, n = 1,128) = 20.085, p = 
0.000; for decreased colon cancer risk: χ2 (1, n = 1,128) = 
29.611, p = 0.000; for decreased obesity risk: χ2 (1, n = 
1,128) = 20.626, p = 0.000). Yet, they were likely to be 
alarmed by bad results (increased colon cancer risk: χ2
(1, n = 1,128) = 105.425, p = 0.000; increased obesity risk: 
χ2 (1, n = 1,128) = 18.064, p = 0.000) and less likely to be 
reassured by good results (decreased colon cancer risk: 
χ2 (1, n = 1,128) = 10.979, p = 0.001; decreased obesity 
risk: χ2 (1, n = 1,128) = 18.760, p = 0.000).
 Interest in Participating in a Genetic Study Conducted 
in a Clinic 
 Seventy-five percent of the students would participate 
in a genetic study within a clinical setting (e.g. in a hospi-
tal). They would thereby agree to undergo a genetic test 
and provide information about their health state and life-
style. The most frequently chosen motive for participa-
tion was contributing to scientific progress followed by 
receiving genetic information about themselves. An 
open-ended option revealed an additional reason which 
we had not included, namely financial compensation for 
participation. Most respondents would like to be in-
formed about their genetic tests results. More than half 
(54%) would like to receive all results irrespective of 
whether preventative or curative measures could be tak-
en, while 37% would want to receive results only for con-
ditions that could be prevented or treated. Male students 
were more likely to want to know all their genetic results 
(χ2 (2, n = 842) = 25.784, p = 0.000). Nine percent of re-
spondents wanted to participate in a genetic study con-
ducted in a clinic but without receiving any results. The 
most frequently chosen reasons by those respondents was 
their concern that they might receive information that 
they did not wish to have, and also that they did not know 
how such results might impact on their families.
 One-fourth (25%) of the respondents did not wish to 
participate in a genetic study in a clinical setting. The 
main reason for that was concern about receiving genetic 
results, while the second most important reason was time 
constraints ( table 2 ;  fig. 1 ). In the open-ended option, re-
spondents provided an additional reason for refraining 
from testing, i.e. the possible consequences that such in-
formation could have on their reproductive choices. To 
the question of what kind of research institution they 
would prefer, our respondents were more likely to par-
ticipate in genetic studies conducted by public institu-
tions (e.g. university hospital) (72.5%) as well as private, 
non-profit institutions (e.g. Cancer Society) (54.1%). For-
profit institutions were not in favor.
 Discussion 
 We found a high level of awareness about DTC ge-
nomics in our study population  [23–27] , something that 
can be explained by the media attention that this issue has 
received in the German-speaking part of Switzerland over 
the last 2 years. In general, most respondents who were 
interested in DTC genomics had a natural science/engi-
neering background. As other studies have shown, early 
Table 3.  Interested in undergoing DTC genomic testing
Yes, n (%) No, n (%) nTotal p value
Gender
Females 294 (52.8) 263 (47.2)
Males 367 (64.8) 199 (35.2) 1,123 0.000
Religion
Religious 44 (35.2) 81 (64.8)
Not religious 586 (62.9) 346 (37.1) 1,057 0.000
Background
Natural sciences 536 (61.6) 334 (38.4)
Humanities 93 (52.5) 85 (47.8) 1,048 0.028
Health Status
Concerned 207 (66.1) 106 (33.9)
Not concerned 105 (54.1) 89 (45.9) 507 0.007
 nTotal ranges between 507 and 1,123 due to a varying total num-
ber of responses. The higher value is indicated in bold, and sig-
nificance was accepted at p < 0.05.
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adopters are interested in genetics or are in general of a 
higher educational level. The key reasons for potentially 
undergoing DTC genomic testing in this study popula-
tion was the opportunity for research participation as well 
as receiving information about health and personal traits. 
These findings are similar to other studies  [9] , although 
it is of particular interest that in our sample research par-
ticipation was highly ranked. The research participation 
motive was mostly chosen by science/engineering and 
medical students. Students studying humanities were 
more motivated by finding out genetic information about 
themselves. It is likely that students engaging with scien-
tific research (e.g. lab, clinic) might be more aware of the 
issues around research participation and may feel more 
inclined to see themselves contributing to such research.
 A total of 41% of the students (n = 465) was not inter-
ested in undergoing DTC genomic testing. Since many of 
the empirical studies have focused on collecting data re-
lating to positive motivation to undergo testing, we have 
less systematic data about why people would refrain from 
testing. Our findings suggest that students, who are con-
cerned about receiving information they might not want 
to know or those feeling that they will get worried about 
their health risks, are less likely to be interested in being 
tested. One of the common arguments in the debate about 
DTC genomics is that individuals will receive informa-
tion that they cannot understand or be able to interpret 
meaningfully, and that they are, therefore, at risk of psy-
chological harm, distress etc.  [16, 21, 28] . Our findings 
suggest that ordinary deliberation evaluating options pre-
cede the decision to undergo a test such as this. It is still 
possible that individuals, who believe they will not be 
worried about genetic results, might nonetheless become 
worried when they actually receive them. However, prev-
alent generalizations about adverse psychological reac-
tions need to take into account the likelihood that those 
susceptible to such reactions will choose not to undergo 
testing. A further observation of interest is that there was 
no strong association between study subject and reasons 
for refraining from testing. The concern about confront-
ing genetic information and bad results (high risks) were 
a primary consideration across all study subjects. There-
fore, the concern about dealing with genetic information 
is probably not necessarily only associated with the ab-
sence of a scientific or technical background (or the work-
Table 4.  Hypothetical high/low genetic risk
Response ↑Colon cancer ↓Colon cancer ↑Obesity ↓Obesity
I would take measures to reduce the risk 605 553 –
I would become lax about taking care of my health – 59 – 120
I would consult a medical doctor 577 45 108 27
I would take note of the results but they would not affect me
due to their merely probabilistic nature 444 749 505 705
I would worry about my health 406 – 125 –
I would be reassured about my health – 339 – 252
I would discuss results with family/friends 221 92 139 75
The results are worthless and I would ignore them 18 65 168 126
Results might
cause worry
Privacy
Low utility
Costs/time
General
scepticism
about genetic
testing
Low validity
DTC genomic testing
Study in clinic
 Fig. 1. Comparison of reasons for not undergoing DTC genomic 
testing vs. not participating in clinical genetic studies. Data has 
been normalized in order to accommodate for varying total num-
ber of times each reason was chosen. Categories have been grouped 
and slightly renamed. 
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ings of science phobia) and may be more related to differ-
ences in personalities, general life views, and life circum-
stance that cut across the science/humanities divide.
 Reactions to mock results showed that increased colon 
cancer risk would likely generate more action including 
involving a medical doctor, while higher obesity risk 
would not do so to the same extent. Respondents might 
have considered colon cancer to be more life-threatening 
than obesity. The fourth most commonly chosen reaction 
was that results would cause alarm. Further analysis 
showed that this option was mostly chosen by those stu-
dents who were not interested in getting tested and who 
had given as a reason for this their concern of becoming 
worried by the results. This is a consistent finding, further 
demonstrating that worrying about results is an impor-
tant concern but, as described above, one that also causes 
reservations about undergoing genetic testing in the first 
place (χ2 (1, n = 1,146) = 248.972, p = 0.000). Neverthe-
less, worrying about genetic information is a broader is-
sue that requires further consideration. One question is 
the extent to which this anxiety is related to perceptions 
about genetics and its predictive power. Another more 
intriguing question is whether anxiety is related to the 
lack of information that is decision-relevant. Can the in-
formation that is obtained from testing be put in use 
when decisions about health, lifestyle, and life in general 
are made? Future studies should investigate these ques-
tions. As Condit  [29] has argued, new genetic technolo-
gies require that people have ‘decision-relevant’ under-
standing of genetics and not merely ‘awareness’ of it. Fur-
thermore, forms of genetic counseling will also have an 
important role to play for those who engage with genetic 
testing.
 It is noteworthy that although in the case of high risk 
regarding both conditions, respondents judged they would 
take action to reduce risk, in the case of low risk their most 
likely reaction was that they will feel unaffected due to the 
results’ probabilistic nature. Even lower ranked the option 
that such results would reassure them of their good health. 
One likely explanation is that bad news in general tend to 
have more impact  [30] , and hence they are more alarming. 
In the case of good news, other issues surfaced, such as 
those about the nature of the tests and their low clinical 
utility. Other studies, however, that have examined experi-
ences of actual test-takers show that users are unlikely to 
act on the results they receive through DTC testing, even 
if at the time of testing they intended to act  [9, 21] . It is 
unclear why DTC genomics results do not seem to have 
either a positive (or negative) effect on actions about health 
 [31] . In our sample, students consistently across the 4 sce-
narios chose the option that the probabilistic nature of re-
sults is such that leaves them unaffected, echoing the low 
clinical utility argument about DTC genomics. It is worth 
exploring whether this view of low clinical utility under-
mines the power of the results in terms of their actionabil-
ity. In addition, it is worth investigating whether this view 
of DTC genomics would also prevent or ameliorate con-
cerns about dealing with the results.
 A number of studies have shown that DTC genomics 
users are motivated to undergo testing due to the oppor-
tunity for research participation. DTC genomics compa-
nies also report a high percentage of their users actually 
contributing to research by consenting to their data being 
used for research as well as by actively filling out question-
naires regarding phenotypic and medical history. Else-
where, we have argued that research participation is an 
aspect of the personal utility that personal genomics may 
have for users  [11, 32] . However, most of the debate about 
DTC genomics has focused on the low clinical utility of 
the tests, leaving the personal utility aspect underexplored. 
As mentioned above, research participation was a signifi-
cant motive for our study population, confirming the sig-
nificance of this utility. We compared this interest in re-
search participation through the DTC path with interest 
in participating in genomic research at the clinic. Most of 
our respondents were also interested in participating in 
genetic research within the clinical setting, and we ob-
served a consistency in this choice amongst those who 
would participate in DTC genomic testing and research. 
Most of those interested in participating were also inter-
ested in receiving all results.
 Students favored to support public, not-for-profit in-
stitutions performing genetic research. We did not ex-
plore the reasons for this preference in this study. Con-
cerns have been raised in the literature about the risk of 
damaging research participants’ trust when data that have 
been collected in the name of a collective research project 
are used for profit making purposes with a limited num-
ber of beneficiaries from the profit. When 23andMe ac-
quired its first patent on a method to ascertain suscepti-
bility to Parkinson’s disease, outrage was expressed in the 
blogosphere at the mismatch of motives between users 
and the company  [33, 34] . In our sample, there was a 
strong preference in favor of the non-profit institutions, 
suggesting that they are viewed as more likely to promote 
the common good than outfits which prioritize profit-
making. In order to harness the willingness of people to 
contribute to genetic research, their attitudes to it, their 
expectations from it, and their assessment of risk and 
benefits should be better understood  [35, 36] . This should 
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include the relationship between interest in genetic re-
search participation and the type of research institution 
people consider trustworthy.
 Privacy concerns and risks of discrimination were 
found to be disincentives to genetic testing and genetic 
research participation in some studies, or at least in stud-
ies that specifically investigated the issue of privacy  [37] . 
However, it is notable that privacy concerns, one of the 
most heavily debated aspects of genetic research, did not 
rank highly in this study population. This is likely to be 
explained by several factors. First, the population we 
studied was young. Young people are often portrayed as 
less concerned about privacy matters, although such re-
ports tend to be anecdotal. Other studies have shown a 
disconnect between the privacy young people would have 
liked to have and the one they end up being offered on-
line. Studies have also shown that younger people tend to 
have a privacy knowledge gap which may explain why 
they tend to be less concerned about it  [38] . It is plausible 
that our students had a similar privacy knowledge gap. 
An alternative explanation may be that given the high lev-
el of privacy protection in Switzerland, the students might 
in general have fewer concerns about suffering privacy 
harms. It is also possible that, in the case of research, an 
acceptable trade-off between privacy and utility (in the 
form of contributing to scientific research) might be at 
play. Some studies have found that individuals accept 
such trade-offs because of the value they attributed to re-
search  [36, 39] . Finally, another explanation might be the 
still fairly low predictive power of genetic information 
which in turn provides relatively limited serious cases for 
concern where privacy might become an issue. As genet-
ics research progresses and potentially becomes more 
predictive, and as more controversial traits are explored 
(e.g. behavioral traits), it is possible that privacy concerns 
might increase.
 Of particular interest were the reasons given by those 
who were not interested in participating in genetic studies 
within the clinical context. Here again, the primary rea-
son was concern about confronting genetic information, 
the same reason that was given for refraining from DTC 
genomic testing altogether. An almost consistent profile 
emerges of the student who avoids genetic information 
irrespective of the context in which such information is 
generated ( fig. 1 ). Those who are uneasy with genetic in-
formation are likely to stay away from this type of infor-
mation no matter what guarantees are in place or what-
ever the level of validity or clinical utility of the results 
might be. By contrast, those who are interested in under-
going genetic tests are also more likely to participate in 
studies in the clinic (χ2 (1, n = 1,104) = 190.549, p = 0.000) 
and willing to be informed about the results (χ2 (2, n = 
831) = 117.728, p = 0.000).
 Limitations 
 Our study is limited as our sample consisted entirely 
of University students, and our findings are, therefore, 
not generalizable to the broader population of the same 
age. Moreover, given that a large number of students who 
received our e-mail invitation did not respond, we might 
have a skewed sample representing those who have a pre-
existing interest in the issue we were investigating. How-
ever, studies about DTC genomics have reported that us-
ers tend to have a higher educational level, an interest in 
biology/genetics, and to be internet savvy. All these are 
characteristics of our respondents. Therefore, our sample 
resembles the likely user of DTC genomics services. An-
other limitation of the study is that it is based on hypo-
thetical scenarios, responses to which may differ from ac-
tual decisions and experience  [38] . However, given that 
the uptake of DTC genomics is low, at least in most Eu-
ropean countries, it is difficult to identify a large sample 
of people who have had such experience. We argue that 
empirical data with hypothetical scenarios still provide 
insights into the motivation and concerns of prospective 
users and can inform the debate about what risk and ben-
efits users might see in DTC genomics as well as the dis-
cussion about appropriate policies.
 Conclusions 
 The emergence of DTC genomics has posed questions 
about risks and benefits to the consumers and has gener-
ated a serious debate. Policy makers in Switzerland and 
elsewhere are currently deliberating appropriate regula-
tory frameworks which are further complicated by the 
fact that such services are offered in online global mar-
kets. The FDA’s recent move has certainly fueled the de-
bate about how we should handle DTC genomics and 
highlighted the need to clarify what the risks and benefits 
of DTC are. However, for a truly informed deliberation, 
it is imperative to have a better understanding of the con-
sumers’ motivations to take up personal genomics ser-
vices, their expectations from it, and their perceptions of 
utility. Our study confirms that there is a relatively high 
interest in DTC genomics at least in this group of young 
people, despite perceiving such testing as having rather 
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limited clinical utility. However, a large number of par-
ticipants was not interested in DTC genomics due to wor-
ries about genetic results. The same reason was cited by 
those who did not want to participate in studies in the 
clinical context. This finding indicates (a) that as is in oth-
er life situations practical deliberation about options pre-
cedes choice, and individuals who worry about receiving 
genetic test results will likely not undergo DTC test, and
(b) that concerns about dealing with genetic information 
is not uncommon and that they can affect interest in
genetic testing for research purposes. Notably, concerns 
about genetic data privacy were low. Concerns about 
dealing with genetic results and limited interest in pri-
vacy issues highlight the need for better and more com-
prehensive public engagement initiatives specifically ad-
dressing younger people. Finally, it is a significant finding 
that research participation seems to be an important per-
sonal utility. This is an underexplored issue that we hope 
further studies will tackle. Given the increasing need for 
genetic data for research purposes, it is important to pay 
attention to the willingness of people to participate in re-
search. If this potential for the common good of research 
were to be harnessed, appropriate opportunities for par-
ticipation should be created and necessary protections 
should be afforded to participants. It is critically impor-
tant to maintain people’s trust and sustain their willing-
ness to be part of the genetic research enterprise.
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